Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder

Journal of Psychiatric Research

Volumn 81, Issue , 2016, Pages 112-118

  Smagula, Stephen F ^a   Wallace, Meredith L ^a   Anderson, Stewart J ^b   Karp, Jordan F ^a,c   Lenze, Eric J ^d   Mulsant, Benoit H ^e   Butters, Meryl A ^a   Blumberger, Daniel M ^e   Diniz, Breno S ^f   Lotrich, Francis E ^a   Dew, Mary Amanda ^a,g   Reynolds, Charles F ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Aripiprazole; Combined moderators; Late life depression; Moderators; Personalized medicine

Indexed keywords

ARIPIPRAZOLE; PLACEBO; VENLAFAXINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; EXPLORATORY RESEARCH; HUMAN; LATE LIFE DEPRESSION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEMORY TEST; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SUICIDAL IDEATION; TRAIL MAKING TEST; TREATMENT RESISTANT DEPRESSION; AGED; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; MIDDLE AGED; NONPARAMETRIC TEST; TREATMENT OUTCOME;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TRAIL MAKING TEST; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 84978872961     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.07.005     Document Type: Article

References (23)

1. Beck, A.T., Kovacs, M., Weissman, A., Assessment of suicidal intention: the scale for Suicide ideation. J. Consult. Clin. Psychol. 47 (1979), 343–352.
2. Buhler, J., Seemuller, F., Lage, D., The predictive power of subgroups: an empirical approach to identify depressive symptom patterns that predict response to treatment. J. Affect. Disord. 163 (2014), 81–87.
3. Cauley, J., The demography of aging. Newman AC, J., (eds.) The Epidemiology of Aging, 2013, Springer, 3–14.
4. Delis DC, K.E., Kramer, J.H., Dellis Kaplan Executive Function System Examiner's Manual. 2001, The Psychological Corporation.
5. Hamilton, M., A rating scale for depression. J. Neurology, Neurosurg. Psychiatry 23 (1960), 56–62.
6. Herr, K.A., Mobily, P.R., Comparison of selected pain assessment tools for use with the elderly. Appl. Nurs. Res. ANR 6 (1993), 39–46.
7. Hsu, J., Mulsant, Lenze, Karp, Lavretsky, Roose, Reynolds, Blumberger, Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation. Am. J. Geriatric Psychiatry, 2016.
8. Joel, I., Begley, A.E., Mulsant, B.H., Lenze, E.J., Mazumdar, S., Dew, M.A., et al. Dynamic prediction of treatment response in late-life depression. The American Journal of Geriatric Psychiatry : Official J. Am. Assoc. Geriatric Psychiatry 22 (2014), 167–176.
9. Kaneriya, S.H., Robbins-Welty, G.A., Smagula, S.F., Karp, J.F., Butters, M.A., Lenze, E.J., et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. (Chicago, Ill) JAMA psychiatry 73 (2016), 329–336.
10. Knol, W., Keijsers, C.J., Jansen, P.A., Belitser, S.V., Schobben, A.F., Egberts, A.C., et al. Validity and reliability of the Simpson-Angus Scale (SAS) in drug induced parkinsonism in the elderly. Int. J. Geriatric psychiatry 24 (2009), 183–189.
11. Kraemer, H.C., Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Statistics Med. 32 (2013), 1964–1973.
12. Lenze, E., Mulsant, B.H., Blumberger, D.M., Karp, J.F., Newcomer, J.W., Anderson, S.J., et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment- resistant depression in late life: a randomized placebo-controlled trial. Lancet, 2015.
13. Montgomery, S.A., Asberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry J. Ment. Sci. 134 (1979), 382–389.
14. Mulsant, B.H., Blumberger, D.M., Ismail, Z., Rabheru, K., Rapoport, M.J., A systematic approach to pharmacotherapy for geriatric major depression. Clin. Geriatric Med. 30 (2014), 517–534.
15. Nelson, J.C., Zhang, Q., Deberdt, W., Marangell, L.B., Karamustafalioglu, O., Lipkovich, I.A., Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Curr. Med. Res. Opin. 28 (2012), 325–334.
16. Oquendo, M.A., Baca-Garcia, E., Kartachov, A., Khait, V., Campbell, C.E., Richards, M., et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J. Clin. Psychiatry 64 (2003), 825–833.
17. Randolph, C., Tierney, M.C., Mohr, E., Chase, T.N., The repeatable battery for the assessment of neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychology 20 (1998), 310–319.
18. Sachdev, P., A rating scale for acute drug-induced akathisia: development, reliability, and validity. Biol. Psychiatry 35 (1994), 263–271.
19. Smagula, S.F., Butters, M.A., Anderson, S.J., Lenze, E.J., Dew, M.A., Mulsant, B.H., et al. Antidepressant response trajectories and associated clinical prognostic factors among older adults. (Chicago, Ill) JAMA Psychiatry, 2015.
20. Thase, M.E., Trivedi, M.H., Nelson, J.C., Fava, M., Swanink, R., Tran, Q.-V., et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim. Care Companion J. Clin. Psychiatry 10 (2008), 440–447.
21. Tibshirani, R., Regression shrinkage and selection via the Lasso. Series B J. R. Stat. Soc., 1994, 267–288.
22. Wallace, M.L., Frank, E., Kraemer, H.C., A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. (Chicago, Ill) JAMA Psychiatry 70 (2013), 1241–1247.
23. Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30 (1992), 473–483.